27 active not recruiting, 24 recruiting, 4 not yet recruiting, 2 suspended. 29 Phase 2, 20 Phase 3, 15 Phase 1, 1 Not applicable.
Follow Sb27: new trials by email Literature Review of Sb27 trials Research Report on Sb27
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 30 | 2026-11-04 | 2026-11-06 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2026-10-01 | 2026-08-20 |
| A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Recruiting | City of Hope Medical Center | 6 | 2026-09-01 | 2026-10-19 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 62 | 2026-07-08 | 2026-10-19 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2026-04-01 | 2026-08-19 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-11-06 |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer Biospecimen Collection, Carboplatin, Cisplatin - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-12-02 | 2026-11-04 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-11-03 |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Biospecimen Collection, Brachytherapy, Carboplatin - Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2025-11-05 | 2026-11-06 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-11-03 |
| Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC Biospecimen Collection, Breast Biopsy Procedure, Carboplatin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Recruiting | Vandana Abramson | 51 | 2025-09-09 | 2025-10-30 |
| Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers Best Practice, Biospecimen Collection, Central Venous Cannula Insertion - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 70 | 2025-08-01 | 2026-05-08 |
Showing 20 of 58. Sign in to see all of them.
Lung Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Urinary Bladder Neoplasms (6) · Carcinoma, Renal Cell (5) · Melanoma (5) · Squamous Cell Carcinoma of Head and Neck (5) · Triple Negative Breast Neoplasms (4) · Brain Neoplasms (3) · Carcinoma (3) · Carcinoma, Transitional Cell (3) · Hypopharyngeal Neoplasms (3) · Laryngeal Neoplasms (3) · Mouth Neoplasms (3) · Ureteral Neoplasms (3) · Carcinosarcoma (2)
National Cancer Institute (NCI) (41) · Mayo Clinic (4) · City of Hope Medical Center (3) · Samsung Bioepis Co., Ltd. (2) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · Vandana Abramson (1)
United States (53) · Canada (11) · Puerto Rico (7) · Guam (5) · Ireland (2) · Japan (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Australia (1) · Bosnia and Herzegovina (1) · Brazil (1) · Georgia (1) · Germany (1) · India (1)
Amer M Zeidan (2) · Aaron S Mansfield (1) · Ahmad Tarhini (1) · Amanda N Fader (1) · Ana C Garrido-Castro (1) · Andrea B Apolo (1) · Anish Thomas (1) · Bently Doonan, MD, MS (1) · Brian C Baumann (1) · Dan P Zandberg (1) · Daniel K. Ebner, MD, MPH (1) · David A Liebner (1) · David E Kozono (1) · Deirdre J Cohen (1) · Diwakar Davar (1)
PMID 33878954, PMID 34340209, PMID 35264434, PMID 35297944, PMID 36416836, PMID 36648215, PMID 36856617, PMID 36972022, PMID 37104746, PMID 37411031, PMID 38236249, PMID 38431043, PMID 39282902, PMID 40044930, PMID 40811146, PMID 40813711, PMID 40966692, PMID 41206673, PMID 41611998, PMID 41747891, PMID 41911908, PMID 42335416
U10CA180820 (10), U10CA180888 (8), U10CA180821 (6), U10CA180868 (6), UM1CA186709 (4), P30CA033572 (3), UM1CA186690 (3), UM1CA186689 (2), P30CA016672 (1), P30CA060553 (1), P30CA068485 (1), U01CA062490 (1), U10CA031946 (1), U10CA180830 (1), UM1CA081457 (1)